Analyst Price Target is $443.00
▲ +12.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $443.00, with a high forecast of $464.00 and a low forecast of $395.00. The average price target represents a 12.64% upside from the last price of $393.30.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Medpace. This Moderate Buy consensus rating has held steady for over two years.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Read More